In vivo CAR-T therapies have grown in demand over time, as scientists have discovered methods to crack the challenges of goal specificity and security, proving to be extra environment friendly than ex vivo remedies for cancers and autoimmune situations.
In typical CAR-T remedy, the method goes one thing like this: A affected person’s T cells are extracted after which they’re shipped to a producing facility and genetically engineered in a lab to precise a chimeric antigen receptor (CAR) — an artificial protein that directs T cells to acknowledge and kill most cancers cells. These altered cells are expanded over a number of weeks, shipped again, and reinfused into the affected person. All this requires the affected person to endure chemotherapy to make room for the CAR Ts.
This course of takes about three to 6 weeks, prices $400,000 to round $500,000 per remedy, requires extremely specialised amenities, some sufferers’ situations worsen whereas ready, and plenty of are merely ineligible.
The core thought behind in vivo CAR-Ts is that it skips all the manufacturing course of, tackling these many challenges. As an alternative of engineering T cells exterior the physique, a supply automobile is injected immediately into the affected person’s bloodstream. That automobile finds circulating T cells, enters them, and delivers the genetic directions to make a CAR, all contained in the affected person’s personal physique.
Because the wait time will get lower considerably, chemotherapy turns into avoidable, doesn’t contain complicated manufacturing, and is extra scalable, it’s seen as a promising development in cell remedy analysis.
Whereas there have been no authorised in vivo CAR-Ts but, as scientists have needed to ace goal specificity and make sure the know-how’s security, the house has considerably expanded over time. Right here are eight in vivo CAR T corporations in preclinical and scientific levels that you need to hold a watch out for.
Umoja Biopharma
Headquarters: Seattle, WA, USALead Candidate: UB-VV111Recent Information: $100 million sequence C spherical in January 2025
Among the many most superior corporations within the in vivo CAR-T house, Umoja Biopharma is one which hasn’t been nabbed by huge pharma but. Based mostly on pioneering work carried out at Seattle Youngsters’s Analysis Institute and Purdue College, the Washington-based biotech has three know-how platforms which are used to design its pipelines.
Its in vivo gene supply platform VivoVec makes use of lentiviral vectors with a T-cell focusing on and activation floor complicated. The lentiviral particles are floor engineered with ligands that bind and transduce circulating T cells within the bloodstream following intravenous infusion. Additional, Umoja’s Rapamycin-Activated Cytokine Receptor system makes use of rapamycin to help CAR-T cell survival and enlargement, bypassing the necessity for chemotherapy-based lymphodepletion. Within the presence of rapamycin, non-transduced immune cells are suppressed, whereas the RACR system in transduced cells converts rapamycin binding to an IL-2/IL-15 sign so as to promote proliferation.
Then, there’s the TumorTag platform. These molecules are used to deliver the cancer-killing T cells near the tumor and the cells surrounding the tumor.
Its lead candidate UB-VV111 is a CD19-targeting in vivo remedy that addresses giant B-cell lymphoma (LBCL) and power lymphocytic leukemia (CLL), for which it was granted quick monitor standing from the U.S. Meals and Drug Administration (FDA) in September final 12 months. It hit the clinic final 12 months, and is being examined as a monotherapy in addition to together with the immunosuppressant rapamycin. The candidate was licensed out to the pharma big AbbVie two years in the past.
Its different scientific candidate is UB-VV400/410 for the blood most cancers non-Hodgkin’s lymphoma and autoimmune situations. It’s a fusion protein designed to generate CD22-directed CAR-T cells inside a affected person’s physique. It’s at the moment being assessed in a part 1 trial having acquired investigational new drug (IND) clearance in late 2024.
The startup final closed a $100 million sequence C spherical in January 2025.
Vyriad
Headquarters: Rochester, MN, USALead Candidate: VV169Recent Information: Secured $25 million in Collection B tranche in December 2025
Based by scientists on the Mayo Clinic in 2015, the Minnesota-based biotech firm has developed its G protein retargeting platforms to create in vivo CAR-Ts.
The corporate’s VSV-GVyriad’s blinded VSV-G platform makes use of lentiviruses. These are engineered with a retargeted VSV-G envelope designed to focus on T cells. By delivering transgenes to particular T cells, it permits for extra environment friendly and fewer poisonous dosing.
The envelopes are blinded, which implies that scientists can safely inject them into the bloodstream to generate practical, tumor-fighting CAR-T cells in vivo. That is higher in comparison with ‘unblinded envelopes’ that require using stimulatory molecules equivalent to CD3/28 beads and focusing on ligands – these litter the viral floor – which improve the chance of off-target activation, in line with Vyriad.
Furthermore, the corporate makes use of its plug-and-play G-Hyperlink protein cap know-how whereby the protein cap binds to the wild-type G protein, detargeting the viral vector by blocking the pure receptors. The platform debuted on the 2026 ASGCT Annual Assembly in Could.
The corporate’s lead candidate VV169 is an in vivo CAR T-cell remedy candidate designed to reprogram a affected person’s T-cells contained in the physique. It targets the B-cell maturation antigen (BCMA), which is usually overexpressed in a number of myeloma cells.
Presently in preclinical research, the corporate introduced promising outcomes late final 12 months. The candidate managed to utterly clear tumors in all of the mice with myelomas in 28 days. It was additionally well-tolerated. Quickly, VV169 will hit the clinic, having been awarded $25 million in a sequence B spherical in December.
Except for simply CAR Ts, Vyriad is creating an oncolytic virus for stable tumors in collaboration with Regeneron in addition to an intravesical remedy for measles infections.
CPTx
Headquarters: Planegg, GermanyRecent Information: Strengthened govt staff by hiring CSO in Could 2026
German biotech firm CPTx, a spin-off from the Technical College of Munich, has created immune-silent single-stranded DNA (ssDNA) vectors to develop in vivo CAR T remedies. Its ssDNA vector platform and its LNP platform differ from viral vectors that completely combine, as they lack viral capsids and permits for repeatable dosing, which isn’t attainable for viral vectors. CPTx’s vector platform is additionally completely different from mRNA vectors because the latter fade too shortly.
The Planegg-based biotech’s lead program is an in vivo CAR T remedy that targets CD19 and CD20 proteins to deal with relapsed and refractory B-cell non-Hodgkin’s lymphoma. The corporate introduced two posters of its in vivo method on the American Society of Gene & Cell Remedy (ASGCT) annual assembly in Boston final month.
In preclinical research, the candidate managed to attain a extra sturdy tumor management in contrast to mRNA-based candidates, which tends to be the case for DNA-based payloads.
Together with American cell and gene therapies firm NanoCell Therapeutics, it was introduced a Eurostars Grant from the European Union by way of the Horizon Europe program and Eureka Community in August final 12 months. That is a part of the QUIET-CAR venture for which CPTx will tackle the event of lipid nanoparticles carrying novel immune-silent ssDNA for in vivo CAR Ts.
Previous to the undisclosed grant, the final time CPTx scooped up funding was in 2024, when it acquired €26 million ($29 million), which went into the event of its platform know-how.
Legend Biotech
Headquarters: Somerset, NJ, USALead Candidate: LB2501Recent Information: Reported first-in-human outcomes for LB2102 in bought tumors in June 2026
Famous for its ex vivo CAR T remedy Carvykti authorised for a number of myeloma in 2024, Legend Biotech additionally has three in vivo CAR T therapies as a part of its roster, all of that are primarily based on its TaVec platform. The platform consists of lentiviral vector engineered to reinforce T-cell specificity, transduction effectivity, and security, whereas limiting transduction of non-T cells. All three ship CAR-T cells in vivo by way of a single intravenous infusion, with out requiring ex vivo cell manufacturing or lymphodepleting chemotherapy.
LB2501 is the New Jersey-based biotech’s CD19/CD20 dual-targeting in vivo CAR-T remedy designed to generate CAR-T cells immediately throughout the affected person following a single intravenous infusion. In its part 1 trial with sufferers with relapsed or refractory B-cell non-Hodgkin lymphoma, at the second dose stage, an general response price (ORR) of 100% was noticed, together with a full response (CR) price of 83.3%, with in vivo CAR-T enlargement and with out lymphodepleting chemotherapy. This knowledge was simply scorching off the press as it was introduced at the European Hematology Affiliation (EHA) 2026 simply this week.
The security profile confirmed no dose-limiting toxicities, no critical adversarial occasions, and no immune effector cell-associated neurotoxicity syndrome (ICANS).
The opposite in vivo CAR Ts are referred to as LB2503 and LB2505, each of that are in part 1 research at current. LB2503 targets GPRC5D and the trial is at the moment enrolling sufferers with relapsed and refractory a number of myeloma. GPRC5D is a validated myeloma goal – it’s the identical antigen focused by J&J’s authorised bispecific antibody talquetamab, identified by its model identify Talvey, making this a high-interest program.
Its third in vivo CAR T remedy LB2505 targets BCMA and has begun its trial in relapsed and refractory autoimmune ailments. LB2505 is a part of a rising variety of in vivo candidates being trialed for autoimmune situations.
Strand Therapeutics
Headquarters: Boston, MA, USALead Candidate: STX-001Recent Information: Introduced a $153 sequence B funding spherical in August 2025
Based by artificial biology pioneers from Massachusetts Institute of Know-how, American biotech Strand Therapeutics has three candidates in its pipeline, all of that are mRNA-based and certainly one of which is an in vivo CAR T remedy referred to as STX-005.
The candidate is a systemically delivered round mRNA that self-generates CAR-T cells to deal with autoimmune ailments and blood cancers. It’s delivered to the cells by SignalPath LNPs, which is used to move programmable mRNA medicines, safely defending the RNA and delivering it particularly to particular cells.
Preclinical knowledge was exhibited at ASGCT final month. The Massachusetts-based biotech Strand has raised over $250 million, having raked in $153 million in a sequence B spherical.
Alaya.bio
Headquarters: New York Metropolis, NY, USARecent Information: Introduced partnership with Nona Biosciences
One other American biotech, Alaya.bio, has engineered an artificial gene supply platform to transport CAR-T cells immediately contained in the affected person.
The know-how consists of a lentiviral vector carrying the therapeutic genetic payload, coating and shielding polymers, and a grafted focusing on agent for selective immune cell engagement, in line with the corporate. With this methodology, there’s then no have to extract, manipulate, and reinfuse affected person cells.
As soon as the remedy is run, the nanoparticle enters and circulates within the bloodstream the place it’s protected by the shielding polymer. It then selectively engages with T cells. The lentiviral cargo is launched and within the case of its lead in vivo CAR T, the genetic directions reprogram the nanoparticles into CAR-T cells within the physique. The assemble makes use of the CD19-1XX CAR with calibrated signaling, which has demonstrated potent efficacy at low cell doses and decreased toxicity in scientific research.
In vivo efficacy knowledge from a research in mice urged that its single intravenous dose of the focusing on nanoparticle was adequate to generate practical CAR-T cells in vivo to ultimately result in tumor management and survival.
Based in 2022, the startup has nabbed $6.5 million in fairness funding and $4 million in non-dilutive funding to this point. It has been in a long-standing partnership with Nona Biosciences to develop CAR-Ts in vivo since 2024. Nona offered entry to antibodies towards a number of targets to validate towards Alaya.bio’s in vivo CAR program.
AAVivo
Headquarters: Houston, TX, USA
Lead Candidate: AVO-100
Latest Information: Introduced knowledge at ASGCT in Boston, MA, in Could 2026
A spinout of the analysis institute Virovek in Texas, AAVivo is without doubt one of the few corporations utilizing an adeno-associated virus (AAV) vector AAV reasonably than lentiviral or lipid nanoparticle (LNP) supply for in vivo CAR-T.
AAVivo is creating its IntelligentAAV (iAAV) platform, which incorporates its Precision AAV Capsid Engineering (PACE) know-how that transforms non-targeted AAV vectors into exact, cell-specific gene supply autos for in vivo era of CAR-T cells. The platform additionally contains BAC-to-AAV know-how for large-scale manufacturing and a Selective Toxin Packaging (SToP) platform with a microRNA security protect for secure supply of potent therapeutic genes. AAVivo is without doubt one of the few corporations utilizing AAV reasonably than lentiviral or LNP supply for in vivo CAR-T.
Its lead candidate is AVO-100, which is designed to generate practical CD19-specific CAR-T cells immediately contained in the affected person after being administered as soon as. Delivered by way of the AAVTCeT capsid, AVO-100 encodes a clinically validated CD19 CAR assemble. Presently within the discovery stage, the objective is to attain fast, deep, and sturdy responses with out the necessity for ex vivo cell manufacturing or lymphodepletion chemotherapy.
AAVivo additionally has AVO-101, a BCMA-directed in vivo CAR-T remedy, AVO-102, a dual-targeted BCMA and CD19 in vivo CAR-T remedy, and AVO-103, an NY-ESO-1–particular in vivo TCR remedy, all of that are additionally of their discovery phases.
Preclinical knowledge from its AAVTCeT platform was introduced at ASGCT this 12 months.
Create Medicines
Headquarters: Cambridge, MA, USALead Candidate: CRT-402Recent Information: $122 million sequence B fundraising spherical in Could 2026
Create Medicines, previously referred to as Myeloid Medicines, has a bunch of in vivo cell therapies; ones that convert into pure killer cells, myeloid cells, and CAR-T cells.
Its lead candidate CRT-402 is an in vivo CAR T remedy that targets the protein CD19 in autoimmune ailments. Its different CAR-T candidate CRT-403 targets the proteins CD19 and BCMA.
The in vivo CAR-T platform demonstrated full B cell depletion and repeatable dosing in a research carried out in non-human primates. Furthermore, its RNA-LNP vector supply system was substantiated as able to deploying CAR and programming immune cells in vivo.
The corporate scooped up $122 million sequence B financing to gas the event of its in vivo CAR pipeline in autoimmune illness and most cancers final month, because it gears for part 1 trials this 12 months.
In vivo CAR-Ts: huge pharma corporations need a huge piece
In vivo CAR-Ts being extremely wanted isn’t any exaggeration. Pharma big Lilly racked up Kelonia Therapeutics for $7 billion in April and Orna Therapeutics and for $2.4 billion in February, each main entities within the in vivo CAR-T discipline and located in Massachusetts.
Gilead-owned Kite Pharma purchased Pasadena-based Interius BioTherapeutics for $350 million in August, and carefully after, it shook palms with Chinese language firm Pregene Biopharma for an as much as $1.64 billion deal to develop in vivo therapies collectively.
AbbVie and Bristol Myers Squibb have been additionally out and about scouting for in vivos final 12 months. AbbVie purchased California-based Capstan Therapeutics for $2.1 billion to attain the rights to CPTX2309, the latter’s lead CAR-T. As Bristol Myers Squibb’s $1.5 billion takeover of Massachusetts-based Orbital Therapeutics late final 12 months gave it the reins of Orbital’s lead candidate OTX-201, finishing investigational new drug (IND)-enabling research and set to hit the clinic quickly.
